The quarter beat on adjusted earnings but slightly missed on revenue. Product revenue was $199.9 million versus a published consensus of roughly $203 million, while adjusted EPS was $1.92 versus approximately $1.72 expected. Adjusted EBITDA reached $113.8 million, up 8% year over year, but the revenue shortfall means the headline operating performance was not a clean beat. (Income Statement; Adjusted EBITDA reconciliation)
| Metric | Q2 2026 | Q2 2025 / expectation | Read |
|---|---|---|---|
| Product revenue | $199.9M | $188.0M / ~$203M consensus | +6% year over year; slight miss to consensus (Income Statement) |
| Adjusted EBITDA | $113.8M | $105.1M | +8% year over year (Adjusted EBITDA reconciliation) |
| Adjusted net income | $75.4M | $64.3M | +17% year over year (Adjusted net income reconciliation) |
| Adjusted EPS | $1.92 | $1.68 / ~$1.72 consensus | Beat (Adjusted net income reconciliation) |
| GAAP net income | $(15.1)M | $12.0M | Reversed to a loss (Income Statement) |
The forward reset is the more important message than the quarterly beat. Full-year product-revenue guidance fell from $865–895 million to $825–855 million, cutting the midpoint by $40 million, while adjusted EBITDA guidance fell from $475–500 million to $445–470 million, a $30 million midpoint reduction. Management attributed both cuts primarily to lower net pricing on authorized-generic Nucynta revenue; JORNAY PM guidance was unchanged, and AZSTARYS guidance increased to $65–75 million from $60–70 million. (2026 Financial Guidance table)
The growth engine is working, but the legacy pain business is deteriorating faster than expected. The ADHD portfolio generated $140.9 million in Q2 revenue, including $12.9 million from AZSTARYS during its partial quarter, while JORNAY PM prescriptions rose 13.1% and its branded long-acting methylphenidate share increased to 29%. Against that, Nucynta franchise revenue fell 24% year over year to $35.2 million, including $5.1 million from authorized generics. The filing therefore supports stronger ADHD execution, but not enough to offset pricing pressure in pain. (Earnings presentation, Recent Business Highlights; Earnings presentation, Product Utilization; Press Release, Commercial Update)
AZSTARYS integration is an operational positive, not yet a proven financial offset. The acquisition closed in May, the expanded sales force was trained ahead of back-to-school demand, and revenue guidance was raised. But the company still expects only a partial-year contribution, while acquisition-related expenses reached $24.1 million in the quarter and intangible amortization was $63.0 million. The claimed long-term benefits remain forward-looking; the immediate filing shows added complexity and spending alongside the new growth opportunity. (Commercial Update; AZSTARYS Portfolio slide; Adjusted EBITDA reconciliation)
The net read is negative because the guidance cut outweighs the EPS beat. Cash and marketable securities fell from $386.7 million at December 31, 2025 to $129.5 million at June 30, 2026, while term notes payable increased to $852.8 million from $571.1 million after the acquisition. The company reports net debt at 2.1 times adjusted EBITDA, leaving less room for execution mistakes. In short: ADHD momentum and adjusted profitability were better than feared, but the market now has to absorb lower full-year revenue and EBITDA expectations, plus greater balance-sheet leverage. (Balance Sheet; Earnings presentation, Disciplined Capital Deployment)
Read the original 8-K on SEC EDGAR ↗